---
schema_version: "secwatch.filing_event.v1"
accession: "0000939767-24-000140"
form_type: "8-K"
ticker: "EXEL"
cik: "0000939767"
company_name: "EXELIXIS, INC."
filed_at: "2024-10-15T23:59:59+00:00"
generated_at: "2026-05-30T15:09:13.069155+00:00"
event_type: "litigation"
sentiment: "positive"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# Exelixis wins patent case against MSN; generic launch blocked until Jan 2030

## Summary
- Delaware court rejected MSN's invalidity challenges to three cabozantinib patents (11,091,439, 11,091,440, 11,098,015), all expiring Jan 15, 2030.
- Court found MSN's ANDA product infringes those three patents; separate patent 11,298,349 (exp 2032) was not infringed.
- Final judgment due Oct 22; FDA cannot approve MSN's generic before Jan 15, 2030 at the earliest.
- Ruling protects Exelixis' cabozantinib franchise from generic entry for over five additional years.

## SEC filing metadata
- accession: 0000939767-24-000140
- form_type: 8-K
- ticker: EXEL
- cik: 0000939767
- company_name: EXELIXIS, INC.
- filed_at: 2024-10-15T23:59:59+00:00
- event_type: litigation
- sentiment: positive
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 8.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/939767/000093976724000140/0000939767-24-000140-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/939767/000093976724000140/exel-20241015.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000939767-24-000140
- JSON: https://secwatch.observer/filing/0000939767-24-000140.json
- Plain text: https://secwatch.observer/filing/0000939767-24-000140.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.